The course of metastatic prostate cancer under treatment

Demir A., Cecen K., Karadag M. A., Kocaaslan R., Turkeri L.

SPRINGERPLUS, vol.3, 2014 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 3
  • Publication Date: 2014
  • Doi Number: 10.1186/2193-1801-3-725
  • Journal Name: SPRINGERPLUS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Keywords: Metastatic prostate cancer, Treatment modality, Course, ANDROGEN-DEPRIVATION THERAPY, CARDIOVASCULAR COMPLICATIONS, HORMONAL-THERAPY, CASTRATION, BLOCKADE, TRIAL, MEN, BICALUTAMIDE, ORCHIECTOMY, MANAGEMENT
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate cancer under treatment.